Reuters -- Drugmaker ImmunoGen Inc said it was discontinuing further internal development of its experimental gastric-cancer drug, IMGN242, citing its slow progress, sending the company's shares down as much as 12 percent.
Reuters -- Drugmaker ImmunoGen Inc said it was discontinuing further internal development of its experimental gastric-cancer drug, IMGN242, citing its slow progress, sending the company's shares down as much as 12 percent.
